The simian immunodeficiency viruses (SIVs) are nonhuman primate lentiviruses related to the human immunodeficiency viruses (HIV-1 and HIV-2), the causative agents of AIDS in humans. SIV has been isolated from several species of Old World primates, including rhesus monkeys (SIVmac) (6) , African green monkeys (SIVagm) (35) , sooty mangabey monkeys (SIVsm) (12, 33) , and mandrills (SIVmnd) (47) . The extensive similarity of SIV to HIV in genetic organization and biological properties suggests that SIV systems are ideally suited for study of AIDS pathogenesis and vaccine strategies. Analysis of nucleotide sequence homology and antigenic cross-reactivity has demonstrated that SIVmac and SIVsm are closely related to HIV-2 (3, 9, 15, 18) . The three viruses SIVmac, SIVsm, and HIV-2 likely comprise a discrete subgroup of primate lentiviruses. Thus, SIV genetic relationships also provide clues to the evolution, origin, and possible interspecies transmission of lentiviruses in primates.
One of the striking features of HIV-1 is the extent of genetic variation among virus isolates (8, 16, 53) . Variation is largely concentrated in the outer membrane protein (gpl20) of the envelope (8, 16, 45) , which is a major target of host immune responses. The transmembrane protein (TMP) of HIV-1 is relatively conserved in its sequence (16, 45) . A major neutralizing epitope in HIV-1 has been localized to one of the variable regions of gpl20, the V3 cysteine loop (14, 37, 40) . In addition, neutralizing epitopes have been identified in other regions of the gpl20 molecule (19, 20) and in the TMP (4, 5, 20) . Neutralizing epitopes in SIV have not * Corresponding author. yet been identified. The extent to which neutralizing epitopes in SIV correspond to those in HIV-1 is not known.
In this report, we identify an SIVmac neutralizing determinant defined by monoclonal antibody (MAb) SF8/5E11 and show that it corresponds to a neutralizing epitope in HIV-1 TMP. The determinant is located in a variable region of the TMP which includes conserved, clustered sites for N-linked glycosylation. Furthermore, genetic drift in this neutralizing determinant was observed in a persistently infected rhesus monkey that was previously inoculated with molecularly cloned SIVmac239 and had a strong antibody response to the infecting virus.
MATERIALS AND METHODS
MAb. MAb SF8/SE11, which recognizes the TMP of SIVmac, was previously isolated by using detergent-disrupted uncloned SIVmac251 as an immunogen (49) . The immunoglobulin subclass of the MAb was determined to be Gl, and it was used as mouse ascitic fluid.
Radiolabeling of cells and immunoprecipitation assay. CEMx174 cells infected with cloned SIVmac251 were labeled with [35S]methionine, and immunoprecipitations were performed as previously described (48) . For (3, 25, 34) . The SIVmac239 lambda clone has been subcloned into two separate DNA segments by using a unique, centrally located SphI site (24) . This generated two pBS (Stratagene) plasmid subclones containing the left half (p239SpSpS') and the right half (p239SpE3') of the viral genome.
Oligonucleotide synthesis. Oligodeoxyribonucleotides were synthesized by the phosphoramidite method on a Cyclone DNA synthesizer (Biosearch), using reaction columns containing derivatized CPG support (Milligen) and purified with C18 Sep-Pak cartridges (Millipore).
Construction of mutants by PCR. Mutants in the viral envelope gene were derived from plasmid p239SpE3' by site-specific mutagenesis using polymerase chain reaction (PCR) (41) . PCR amplifications were performed with an automated DNA Thermal Cycler (Perkin-Elmer Cetus) for 20 cycles (each consisting of a 1-min 94°C denaturation, a 2-min 55°C annealing, and a 5-min 72°C extension step), followed by a single 10-min extension at 72°C. Then 1 ,M each primer, 2.5 U of Taq polymerase, 1.5 mM MgCl2, and 200 ,uM each deoxynucleoside triphosphate were used in the PCR reaction mixture.
Site-specific mutagenesis by overlap extension (SOE) requires introduction of nucleotide changes within oligonucleotide PCR primers and a secondary PCR amplification to incorporate changes into an internal site within the amplified DNA fragment (21, 22) . Two mutants with defined substitutions within the envelope TMP of SIVmac239 were generated by using pairs of complementary mutagenic oligonucleotide primers representing nucleotides 8491 to 8517 (38) . Primer 5'-CCA AAG TGG AAC AAT GAT ACT TGG CAA-3' and its complementary oligonucleotide were used to generate mutant p239SpE3'tm-1, and primer 5'-CCA GAT TGG AAC AAT GAT ACT TGG CAA-3' and its complement generated mutant p239SpE3'tm-2. Underlined letters identify nucleotide changes that were introduced. The outer set of oligonucleotide primers consisted of 5'-AGTGCA GAGGTGGCAGAACT-3' (8050 to 8069) and 5'-TGTCCCT CACAAGAGAGTGAGCTCAAGCCC-3' (9220 to 9249). Two segments (8050 to 8517 and 8491 to 9249) were generated in separate reactions, each containing one set of outer and inner mutagenic primers and 0.1 ,ug of plasmid p239SpE3'. For overlap extension by PCR, amplified products from the first round of PCR which shared overlapping sequences at the ends to be joined were purified from an agarose gel and mixed in a subsequent PCR reaction containing additional outer primer pairs. The resulting PCRgenerated recombinant products were purified from an agarose gel and restricted with ClaI and BglII, and the fragments were inserted into the ClaI-BglII site of p239SpE3'. Since the recombinant plasmid (p239ABglII) lost the 2.8-kb BglII fragment containing the 3' long terminal repeat region through the cloning step, the fragment was reinserted to generate p239SpE3'tm-1 and p239SpE3'tm-2.
The nucleotide sequence surrounding the site of SOE in the mutant clones was confirmed by primer-directed dideoxychain termination sequencing (42) .
DNA transfection. An SIVmac239 left-half clone (p239SpSpS') was ligated with parental and mutant right-half clones after digestion with SphI and transfected into CEMx174 cells with DEAE-dextran (34) . Virus replication was monitored by measurement of reverse transcriptase activity in the culture supernatant. Virus particles concentrated from the culture supernatant were used for immunoblot analysis (27) .
Analysis of envelope variability in vivo. Total cell DNA was prepared from peripheral blood mononuclear cells at 69 and 93 weeks postinfection and from a lymph node biopsy taken at 69 weeks from a rhesus monkey persistently infected with molecularly cloned SIVmac239. A fraction of the lymph node taken at 69 weeks and a fraction of the peripheral blood mononuclear cells taken at 93 weeks were each cocultivated with CEMx174 cells for a total of 51 and 41 days, respectively, and the recovered virus was used to prepare Hirt supernatant DNA. The total cell and Hirt supernatant DNAs were used as templates in PCR to specifically amplify full-length env sequences between nucleotides 6544 and 9249 (38) . For the total cell DNAs, two rounds of 30 PCR cycles were performed. The first round of PCR was performed with an outer set of oligonucleotide primers (6474 to 6493 and 9279 to 9298), while the second round was performed with an inner set of primers (6544 to 6573 and 9220 to 9249) complementary to the amplified product of the first round. For the Hirt supernatant DNAs, only the inner set of primers was used in one round of PCR. The inner primers contained SstI sites for cloning. The PCR reaction conditions were in accordance with those of the manufacturer (Perkin-Elmer Cetus), and the following cycle profile was used: denaturation at 94°C for 1 min, annealing at 55°C for 2 min, and extension at 72°C for 3 min. An autoextension of 10 s was added to each PCR cycle, and a 10-min final extension at 72°C was added to the last cycle. The 2.7-kb amplified env fragments were restricted with SstI and cloned into pBS-(Stratagene) for subsequent double-stranded DNA sequence analysis.
Nucleotide sequence accession number. The SIVmac239 sequence reported here has been filed with the GenBank data base under accession number M33262. uncloned SIVmac251 but did not cross-react with SIVsm or SIVmne (49) . Therefore, the MAb seemed to recognize a specific epitope in SIVmac TMP. The MAb predominantly precipitated envelope precursor (gp160) from metabolically labeled CEMx174 cells infected with cloned SIVmac251 (Fig. 1, lane 1) . After tunicamycin treatment of the same cells to block the synthesis of the dolichol phosphate-linked oligosaccharide precursor (10) , the MAb precipitated a polypeptide of 80 kDa, which is approximately the predicted size of the unglycosylated form of the envelope precursor of SIVmac251 (Fig. 1, lane 2) . Therefore, SF8/5E11 recognized an epitope located in the protein backbone of SIVmac TMP, and carbohydrates were apparently not involved in the MAb recognition.
RESULTS

Strict
Reactivity with three molecular clones of SIVmac was analyzed by immunoblotting to examine whether the epitope recognized by the MAb was commonly present in SIVmac (Fig. 2) . The SIVmacl42 and SIVmac251 cloned viruses have truncated forms of TMP (28 to 30 kDa; Fig. 2 ), reflecting the presence of in-frame stop codons in their TMP coding regions (3, 27, 34) ; the SIVmac239 infectious clone does not have a premature in-frame stop codon in its TMP coding region, and it produces virus with full-length (41-kDa) TMP following short-term culture in the human CD4-positive cell line CEMx174 (Fig. 2) (27) . The MAb reacted strongly with the 30-kDa TMP of cloned SIVmac251. However, the MAb reacted only very weakly with TMP of cloned SIVmacl42 (the reactivity cannot be seen in Fig. 2) , and it did not react detectably with cloned SIVmac239.
To determine whether the epitope recognized by the MAb in the TMP was expressed on the surface of cells infected with SIVmac251, we performed a live-cell immunofluorescence assay. CEMX174 cells infected with SIVmac251 were incubated with a 1:100 dilution of SF8/SE11, washed, and then incubated with fluorescein isothiocyanate-conjugated goat antimouse immunoglobulin G. Cells were further washed and examined under a fluorescence microscope. Expression of the epitope recognized by the MAb was clearly detected on the surface of the infected cells (data not shown).
To examine potential biological activity of the MAb, two
Strain-specific reactivity of MAb SF8/SE11 to cloned SIVmac251 TMP by immunoblotting. The SIVmacl42, SIVmac239, and SIVmac251 cloned viruses were concentrated from the culture supernatants and analyzed for immunoblot reactivity, using SIVmac-positive rhesus monkey sera (Pos. Cont) and MAb SF8/SE11. The size of each TMP is indicated. assays were performed. In a cell-free virus neutralization assay (Fig. 3) , cloned SIVmac251 and cloned SIVmac239 were used to infect HUT-78 cells and CEMx174 cells, respectively. MAb SF8/SE11 exhibited neutralizing activity with cloned SIVmac251 cell-free virus, but it did not neutralize cloned SIVmac239 virus. The MAb was also examined for its ability to inhibit syncytium formation between uninfected and infected CEMx174 cells (Table 1) . Inhibition of syncytium formation by SF8/SE11 was also strain specific. The MAb inhibited syncytium formation with cloned SIVmac251-infected cells, but it did not prevent syncytium formation with cloned SIVmacl42-and cloned SIVmac239-infected cells. Thus, the strict strain specificity of the MAb with respect to reactivity on immunoblots paralleled results with the biological assays.
Identification of determinants of strain specificity. These data indicated that the MAb recognized a specific neutralizing determinant within a variable region of the SIVmac TMP. We compared the TMP sequences of the three SIV mac infectious clones to obtain insight into the epitope recognized by MAb SF8/SE11. The sequences of SIVmacl42 TMP (3) and SIVmac239 TMP (27) have been previously published. We sequenced DNA in the TMP region of the SIVmac251 infectious clone and compared it with the previously published sequences (Fig. 4) (Fig. SA) . The strategy for site-specific mutagenesis is outlined in Fig. 6 and in Materials and Methods. The mutant forms were confirmed by DNA sequencing. Plasmid DNAs with the described mutations were transfected into CEMx174 cells, and virus production was monitored by assay of reverse transcriptase activity. The mutant viruses were fully replication competent. Virus particles were concentrated from the culture supernatant 2 weeks after transfection and analyzed by immunoblotting. Although the predicted molecular weights of the TMP polypeptide backbones of SIVmac239, SIVmac239tm-1, and SIVmac239tm-2 are essentially the same, SIVmac239tm-1 TMP was approximately 2 kDa smaller than wild type and SIVmac239tm-2 by SDS-PAGE (Fig. 5B) . SIVmac239tm-1 showed only weak reactivity to MAb SF8/SE11. However, SIVmac239tm-2 with changes at both positions 106 and 110 reacted strongly with the MAb, as strongly as SIVmac251 (Fig. SB) . Thus, the TMP amino acid sequence Asp-TrpAsn-Asn-Asp at position 106 to 110 determines the strainspecific reactivity and neutralization by SF8/SE11. Samples (1 VLg) of overlapping peptides 25 Genomic variation. This strain-specific neutralizing determinant is located within a variable region of SIVmac which includes three potential sites for N-linked glycosylation (N-X-S or N-X-T, where X is any amino acid) (Fig. 7) . The TMP amino acid sequences are generally well conserved among SIVmac, SIVsm, and HIV-2 (75 to 89% overall homology); this conservation is especially evident in the amino-terminal region, which shows 90% identity (18, 54) . The three potential N-linked glycosylation sites are completely conserved among SIVmac, SIVsm, and HIV-2 ( Fig.  7) , but extreme sequence variation is observed between and around the clustered N-linked glycosylation sites, including the neutralizing determinant of MAb SF8/SE11. Furthermore, this region corresponds exactly to an antigenic, slightly variable (30, 52) , weak neutralizing epitope (20) in HIV-1 TMP which also includes conserved, clustered sites for N glycosylation (Fig. 7) . HIV-1 env aa 612 to 635 (HIV-1 TMP aa 101 to 124) were previously reported by Ho et al. (20) to be a weak neutralizing epitope. (See Fig. 6 ). The virus was concentrated from the culture supernatants and analyzed for immunoblot reactivity with MAb SF8/SE11. The size of each TMP is indicated. Pos. Cont, SIVmac-positive rhesus monkey serum; wt, parental, wild-type SIVmac239. in the envelope have properties of predicted high antigenicity (30, 45) , pressures from the host immune response to infection may select for variant virus strains. In fact, the RP135 epitope in hypervariable region V3 of gp120 has been identified as a major, strain-specific neutralization epitope of HIV-1 (14, 37, 40) . Alignment of the predicted envelope protein sequences of SIVmac, SIVsm, and HIV-2 also shows alignment of conserved and variable domains and apparent conservation of overall structure (3, 15, 18, 54) . The strain-specific neutralizing determinant described in this report is located within a variable region of the TMP that includes conserved sites for N-linked glycosylation and is flanked by conserved domains. This region exactly corresponds to the antigenic, slightly variable (30, 52) , weak neutralizing epitope (20) in the TMP of HIV-1 which also has conserved N-linked glycosylation sites.
The SIVmac239 molecular clone causes fatal immunodeficiency in approximately 50% of rhesus monkeys within 1 year of infection (24) . The strength of the antibody response in infected monkeys can be predictive of the outcome of infection; monkeys with weak antibody responses die within 6 months with AIDS (7, 24) . However, longer-term survivors with strong antibody responses remain persistently infected (7, 24) . Recent results suggest that genetic variants in env are selected during persistent infection of rhesus monkeys with molecularly cloned SIVmac239 (2). All 16 clones that were analyzed in the current study exhibited extensive sequence changes within and around the strain-specific neutralizing determinant defined by MAb SF8/SE11 (Fig. 8) . Thus, this variable, strain-specific, neutralizing determinant is likely to be a critical target or to interact with a critical target of the host immune response; flexibility of sequence in this region may facilitate continued survival and persistence of the virus in the presence of an active immune response. For two other lentiviruses, equine infectious anemia virus and visna virus, progressive changes in the envelope gene have been suggested to be directly responsible for the periodic or chronic course of the disease (32, 36, 43) .
The env gene products of HIV and SIV are heavily glycosylated proteins, and potential sites of N-linked glycosylation are well conserved (45, 52) . The importance of N-linked glycosylation for early stages of HIV-1 entry has been described previously (17, 31, 51) . Sequence analysis predicts three potential sites for N-linked glycosylation in the TMP of SIVmac. These three sites, which are well conserved in SIVmac, SIVsm, and HIV-2, all cluster around the neutralizing determinant defined by SF8/SE11. Although considerable variation in the SIV TMP neutralizing determinant was observed in vivo in our current study, all 16 clones preserved sites for N-linked glycosylation, including the 8 clones in which one glycosylation site was displaced (Fig. 8) (18), HIV-2ROD (15) , HIV-2N1H-z (54) , HIV-21sy (11) , and HIV-lBHIo (50) (23) .
Sequence variation in the 106 to 110 region of SIV TMP was much more limited in the seven clones from recovered virus than in the clones directly obtained from peripheral blood or lymph node (Fig. 8) (44) .
Several functional epitopes in the TMP of HIV-1 have been identified previously, including a fusion domain (13, 28) , neutralization epitope (4, 5, 20) , immunosuppressive domain (26, 39) , and cytotoxic T-lymphocyte epitope (46) . The fusion domain of SIVmac has been localized to the amino terminus of the TMP (1), just as in HIV-1. However, other functional domains of SIV TMP have not been identified. The strain-specific neutralizing determinant in the variable region of SIVmac TMP demonstrated in this report corresponds in location to a variable, neutralizing epitope previously identified in HIV-1. Thus, the location of at least one neutralizing epitope appears to be common to both SIVmac and HIV-1. Continued studies along these lines will be important for validating SIV models for vaccine develop- 
